Immunotherapeutically-targeting IDO1 in Pediatric High-grade Glioma

Cancer Immunotherapy is a therapy which uses the patient’s own immune system to destroy tumors. This strategy is considered particularly promising for patients with high-grade pediatric brain cancer, whose survival rate is currently 10-15% despite use of aggressive surgical and radiation treatments. Immune cells are capable of the destruction of glioblastoma (GBM), but research into adults with GBM has shown a direct relationship between heightened levels of enzymes that suppress the immune system and a lowered survival rate. The impact of levels of these same enzymes in patients with pediatric brain cancer has yet to be explored. Using the Pediatric Brain Tumor Atlas, researchers seek to address this knowledge gap alongside other immune system analysis.